BioAlliance Pharma receives market approval
Paris, January 09, 2008 - BioAlliance Pharma SA (Euronext Paris - ticker code BIO) today announces, following the end of the European Mutual Recognition Procedure last December (with France as Reference Member State) that it has just received the Marketing Authorisation for Loramyc® in the UK and Denmark.
The grant of the Marketing Authorisation in the UK represents an important milestone for BioAlliance Pharma especially with the payment of €2.5 million by its partner SpePharm, according to the terms of the agreement signed in March 2007, which led to the creation of the SpeBio JV for the distribution of Loramyc® in Europe.
More info on BioAlliance's website or on the press release
Next > elbion partners with Oakwood Laboratories for sustained release Naltrexone treatment for alcohol dependence Previous > Luc Peeters heads up Amplexor’s consulting team |
